Cancer patients in Tulsa and northeastern Oklahoma will have access to a larger number of cancer clinical trials sponsored by the National Cancer Institute through a recent affiliation agreement between the Tulsa Cancer Institute and the Stephenson Cancer Center in Oklahoma City. These clinical trials provide patients and physicians new strategies for the early detection and treatment of cancer.
“We are very pleased that the Stephenson Cancer Center will be able to expand its ability to help Oklahomans across our entire state,” said OU President David L. Boren.
“We are very pleased to collaborate with the Tulsa Cancer Institute, the largest private oncology practice in the state, to offer a wider number of clinical trials to patients in Tulsa and the northeastern part of Oklahoma,” said Stephenson Cancer Center Director Dr. Robert Mannel. “This is win-win arrangement for all involved, bringing the Stephenson’s large portfolio of NCI clinical trials to patients receiving care at the Tulsa Cancer Institute.”
The Stephenson Cancer Center currently offers more than 300 clinical trials to test new treatment and detection strategies for all types of cancer. In addition, it offers clinical trials designed to evaluate new strategies for managing symptoms and enhancing quality of life. More than 1,300 cancer patients annually participate in these clinical trials. The Oklahoma TSET Phase I Program, housed at the Stephenson Cancer Center, provides patients who have failed standard line therapies with early access to the newest molecularly-targeted drugs.
Tulsa Cancer Institute physicians have a long history of providing opportunities for Oklahomans to participate in cancer clinical trials. Through its affiliation with the Stephenson Cancer Center, an expanded array of National Cancer Institute clinical trials will be available to the patients of the Tulsa Cancer Institute. Patients will be able to participate in these clinical trials while receiving treatment at a participating Tulsa Cancer Institute location.
“Providing patients with options to participate in clinical trials raises the standard of cancer care for all Oklahomans,” noted Dr. Daron Street, an oncology specialist at the Tulsa Cancer Institute. “Through this affiliation, Tulsa Cancer Institute physicians now have even more clinical trial options to offer patients who want to make a difference in the fight against cancer.”